Amfetamiini

Amfetamiini is a psychostimulant drug that belongs to the family of amphetamine class of substances. It is commonly referred to as a recreational or illicit drug, but it is also used in various medical contexts, such as in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. In Finland, where the Finnish name "Amfetamiini" is used, it is recognized as a scheduled substance, restricted for use under the Finnish Medicines Act.

Pharmacologically, amfetamiini acts as a central nervous system (CNS) stimulant, producing effects such as increased alertness, energy, and focus. It achieves this by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. This mechanism of action is responsible for both the therapeutic benefits and the potential for misuse of the substance.

Medically, amfetamiini is used under the brand names Pexeva and Evekeo among others. The medicine is available in various formulations, including immediate-release and extended-release capsules, as well as oral and injectable formulations. The treatment typically involves a combination of pharmacological and non-pharmacological interventions, tailored to the individual's specific needs and circumstances.

However, the recreational use of amfetamiini has been associated with a range of adverse effects. Chronic use has been linked to psychological and physical dependence, while acute overdose can lead to cardiovascular complications, hypertension, and possibly even death. Additionally, amfetamiini use has been connected to various social concerns, such as lower academic performance, poorer relationships, and an increased risk of mental health problems.

More research would be needed to understand the potential risks and benefits better, while avoiding unnecessary bias with objective and relevant sources to present a comprehensive official understanding.